What is the clinical evidence from this study?

Study design: Review. Population: Pulmonary hypertension. Intervention: Pulmonary hypertension treatments.

What does this research mean for the field?

Recent advances in pulmonary arterial hypertension treatments have introduced therapies targeting underlying vascular abnormalities, while treatment strategies for non-Group 1 forms of pulmonary hypertension remain limited. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the evolving treatment landscape for pulmonary hypertension, examining the transition from conventional vasodilators to novel disease-modifying agents that target vascular remodeling.

August 2, 2026Clinical and Translational ScienceOpen Access

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

View Full Paper

Ask AI

Bookmark

Key result

Novel pulmonary hypertension therapies like sotatercept shift treatment from vasodilation toward disease modification.

Why the study?

While PAH treatment has advanced, strategies for other forms of PH remain limited, though novel therapeutic targets and investigational agents are emerging.

Key Points

To review the evolving treatment landscape for pulmonary hypertension, examining the transition from conventional vasodilators to novel disease-modifying agents that target vascular remodeling.
Narrative review evaluating clinical guidelines, pathophysiological mechanisms across WHO Groups 1–5, and foundational genetic pathways involving BMPR2 and TGF-β signaling.
Summarized therapeutic evidence from Phase 3 clinical trials (STELLAR, ZENITH, and HYPERION) investigating the activin signaling inhibitor sotatercept as add-on therapy in pulmonary arterial hypertension.
Traditional therapies acting on endothelin, nitric oxide, or prostacyclin pathways promote vasodilation and delay progression, but do not reverse underlying vascular remodeling or normalize 5-year survival.
In the ZENITH Phase 3 trial of participants at high risk of death, sotatercept reduced the risk of morbidity or mortality by 76% versus placebo.
In the HYPERION Phase 3 trial of participants within one year of diagnosis, sotatercept reduced the occurrence of clinical worsening events by 76% versus placebo.

PICO

Population

Pulmonary hypertension

Intervention / Comparator

Pulmonary hypertension treatments

The treatment paradigm for pulmonary arterial hypertension is shifting towards disease-modifying therapies that target underlying vascular remodeling, offering hope for improved long-term outcomes.

Limitations

Translating vascular remodeling findings from preclinical models to clinical efficacy in PH is challenging
Establishing the extent and durability of true vascular remodeling in humans remains an important translational gap
Diagnostic challenges and misclassification of patients can affect clinical trial results
Accurate diagnosis and classification according to PH group can be challenging, with misclassification likely to affect clinical trial results
Evidence is still lacking on whether time to clinical worsening is a valid surrogate for mortality

Implication

Supports evolving PAH strategies with disease-modifying options; leaves open long-term outcome data from prospective trials.

Abstract

Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated. PH is classified into five groups (WHO Groups 1-5) based on etiology and pathophysiology. Group 1 PH, known as pulmonary arterial hypertension (PAH), has seen recent therapeutic advances with life-extending treatments, including a new therapeutic option that targets the underlying vascular abnormalities. PAH treatment guidelines now emphasize early diagnosis, risk stratification, and targeting multiple pathophysiologic pathways with upfront combination therapy. In contrast to PAH treatment, strategies for other forms of PH remain limited and focus on managing pathophysiologic processes outside the pulmonary vasculature, including left heart disease (Group 2), lung disease and/or hypoxia (Group 3), or pulmonary artery obstructions (Group 4). Nevertheless, advances in research have introduced novel therapeutic targets and investigational agents, offering hope for future expanded treatment options. In this review, we explore recent advances in PH treatments, highlighting the developments poised to expand the therapeutic landscape for this complex disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by Clinical and Translational Science · CC BY-NC-ND

Cite This Study

Ayalasomayajula et al. (2026) conducted a review in Pulmonary hypertension. Pulmonary hypertension treatments was evaluated. Recent advances in pulmonary hypertension treatments, notably the approval of the activin signaling inhibitor sotatercept, are shifting the therapeutic landscape from vasodilation to disease modification.

synapsesocial.com/papers/6a6eeb4d1b0468a7eeab4553 https://doi.org/10.1111/cts.70685

View Full Paper

Ask AI

Bookmark

Implication

Supports evolving PAH strategies with disease-modifying options; leaves open long-term outcome data from prospective trials.

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Figures from the paper

Cite This Study

Keep reading

Keep reading